These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26509831)

  • 1. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
    Zhan P; Pannecouque C; De Clercq E; Liu X
    J Med Chem; 2016 Apr; 59(7):2849-78. PubMed ID: 26509831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017).
    Zuo X; Huo Z; Kang D; Wu G; Zhou Z; Liu X; Zhan P
    Expert Opin Ther Pat; 2018 Apr; 28(4):299-316. PubMed ID: 29411697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.
    Kang D; Song Y; Chen W; Zhan P; Liu X
    Mol Biosyst; 2014 Aug; 10(8):1998-2022. PubMed ID: 24841339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.
    Huang B; Kang D; Zhan P; Liu X
    Expert Opin Drug Discov; 2015 Dec; 10(12):1271-81. PubMed ID: 26372893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance.
    Yin PD; Das D; Mitsuya H
    Cell Mol Life Sci; 2006 Aug; 63(15):1706-24. PubMed ID: 16715409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease.
    Li N; Ainsworth RI; Ding B; Hou T; Wang W
    J Chem Inf Model; 2015 Jul; 55(7):1400-12. PubMed ID: 25993532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs for old.
    Winston A; Stebbing J
    J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspects of successful drug discovery and development.
    Pauwels R
    Antiviral Res; 2006 Sep; 71(2-3):77-89. PubMed ID: 16828174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.
    Maeda K; Das D; Kobayakawa T; Tamamura H; Takeuchi H
    Curr Top Med Chem; 2019; 19(18):1621-1649. PubMed ID: 31424371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basic approaches to anti-HIV resistance].
    Baba M
    Nihon Rinsho; 2002 Apr; 60(4):763-8. PubMed ID: 11968785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
    Shenderovich MD; Kagan RM; Heseltine PN; Ramnarayan K
    Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodrugs of HIV protease inhibitors.
    Vierling P; Greiner J
    Curr Pharm Des; 2003; 9(22):1755-70. PubMed ID: 12871195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties.
    Subbaiah MAM; Meanwell NA; Kadow JF
    Eur J Med Chem; 2017 Oct; 139():865-883. PubMed ID: 28865281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a new HIV-1 inhibitor scaffold and synthesis of potential prodrugs of indazoles.
    Kim SH; Markovitz B; Trovato R; Murphy BR; Austin H; Willardsen AJ; Baichwal V; Morham S; Bajji A
    Bioorg Med Chem Lett; 2013 May; 23(10):2888-92. PubMed ID: 23566519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of resistance testing in South Trinidad.
    Duke N; Aboh S; Bosivert N
    West Indian Med J; 2010 Jul; 59(4):400-2. PubMed ID: 21355515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genotypic antiretroviral resistance testing and phylogenetic analysis of protease and reverse transcriptase in antiretroviral drug-naïve AIDS patients in Henan province].
    Yang K; Li JY; Bao ZY; Li HP; Li L; Zhuang DM; Wang Z; Li H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2005 May; 26(5):351-5. PubMed ID: 16053762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase.
    Sweeney ZK; Acharya S; Briggs A; Dunn JP; Elworthy TR; Fretland J; Giannetti AM; Heilek G; Li Y; Kaiser AC; Martin M; Saito YD; Smith M; Suh JM; Swallow S; Wu J; Hang JQ; Zhou AS; Klumpp K
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4348-51. PubMed ID: 18625554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
    Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
    J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.